IRIDEX to Showcase Cyclo G6™ Laser System Equipped with MicroPulse® Tissue Sparing Glaucoma Technology at American Academy of Ophthalmology (AAO) Meeting

Glaucoma System to Make First Ever AAO Appearance at 119th Annual Meeting

Nov 11, 2015, 06:30 ET from IRIDEX Corporation

MOUNTAIN VIEW, Calif., Nov. 11, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced its attendance at the 119th annual American Academy of Ophthalmology (AAO) Meeting. The Company will feature its latest product, the Cyclo G6™ laser system equipped with MicroPulse tissue sparing glaucoma technology for the treatment of a range of glaucoma disease states. This will be the first time the Cyclo G6 will be demonstrated at the AAO Annual Meeting, the industry's foremost conference in vision research and innovation. The Meeting will be held from November 14-17th in Las Vegas.

Glaucoma is a chronic, global disease and the leading cause of adult irreversible blindness.  The patient population continues to grow, affecting more than 4 million people in the U.S. and approximately 60 million people worldwide.  

Tissue-sparing MicroPulse therapy, which can be performed on the Cyclo G6 via the newly-patented MicroPulse P3 (MP3) probe, is designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma-dedicated laser along with a family of single use probes, as well as the newly patented MP3 disposable. The Cyclo G6 also offers repeatable and minimally invasive approaches which may slow the progress of the glaucoma.

"We have found that the MicroPulse P3 therapy has the potential to address a significant unmet need in reducing ocular pressure in patients with glaucoma without having to perform an incision," said Nathan M. Radcliffe, M.D., New York Eye Surgery Center. "The technology is easily administered, and often reduces the need for daily eye drop regimens, a considerable improvement for patients who may be prone to missing these critical treatments."

"The MicroPulse system for the treatment of glaucoma along with MicroPulse P3 disposable probes underscore our evolving razor, razorblade business model that focuses on the sale of follow-on disposables that address glaucoma at its early, middle and late stages of development," said William M. Moore, President and Chief Executive Officer of IRIDEX.  "It is a safe, cost-effective modality that is also in line with our goal of providing value-based medical technologies."

About MicroPulse Technology MicroPulse is a tissue-sparing laser delivery therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning its future marketing initiatives, including those matters related to the upcoming AAO Annual Meeting, trends in treatment and product adoption and usage, product plans and future product releases, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 3, 2015, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Logo - http://photos.prnewswire.com/prnh/20141001/149809

 

SOURCE IRIDEX Corporation



RELATED LINKS

http://www.iridex.com